Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α. (Q54325989)
Jump to navigation
Jump to search
scientific article published on 22 August 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α. |
scientific article published on 22 August 2014 |
Statements
Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α. (English)
1 reference
Astrid M Pedersen
Anne E Lykkesfeldt
22 August 2014
1 reference